✦ LIBER ✦

Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid : Results in 98 patients

✍ Scribed by Shawn D. Safford; R. Edward Coleman; Jon P. Gockerman; Joseph Moore; Jerome Feldman; Mark W. Onaitis; Douglas S. Tyler; John A. Olson Jr.

Publisher: John Wiley and Sons
Year: 2004
Tongue: English
Weight: 246 KB
Volume: 101
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.20592

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dosimetry of iodine 131 metaiodobenzylgu

Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study

✍ S. L. Fielding; M. A. Flower; D. Ackery; J. T. Kemshead; L. S. Lashford; I. Lewi 📂 Article 📅 1991 🏛 Springer 🌐 English ⚖ 876 KB

Iodine-131 treatment and high-resolution

Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma

✍ Seyfettin Ilgan; A.Ozgur Karacalioglu; Yuksel Pabuscu; G.Kaan Atac; Nuri Arslan; 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 175 KB

Doxorubicin-paclitaxel : A safe regimen

Doxorubicin-paclitaxel : A safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European Organization for Research and Treatment of Cancer multicenter trial

✍ Laura Biganzoli; Tanja Cufer; Peter Bruning; Robert E. Coleman; Luc Duchateau; B 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 2 views

## Abstract ## BACKGROUND The potential cardiotoxicy of the doxorubicin‐paclitaxel regimen, when paclitaxel is given shortly after the end of the anthracycline infusion, is an issue of concern, as suggested by small single institution Phase II studies. ## METHODS In a large multicenter Phase III

Interferon-α-2a with or without 13-cis r

Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma : Results of a randomized Phase II study (European Organization for Research and Treatment of Cancer Study 30951)

✍ Sophie D. Fosså; Gerald H. J. Mickisch; Pieter H. M. De Mulder; Simon Horenblas; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin